Researchers at the University of Illinois have identified biomarkers that can be used to determine ovarian cancer survival and recurrence, and have shown how these biomarkers interact with each other to affect these outcomes. The team used data from the Cancer Genome Atlas, which contains information about ovarian cancer patients’ age, survival, cancer recurrence, treatment, tumor stage, tumor grade, and genomic expression.
To get a better understanding of metastasis, more than 95 graduate students, post docs and professors in a variety of laboratories across the U.S. subjected two cell lines to a battery of tests and measurements using more than 20 different techniques. The work has enabled a comprehensive cataloging and comparison of the physical characteristics of non-malignant and metastatic cells.
Cancer cells that can break out of a tumor and invade other organs are more aggressive and nimble than nonmalignant cells, according to a new multi-institutional nationwide study. These cells exert greater force on their environment and can more easily maneuver small spaces.
Doctors have begun to categorize breast cancers into four main groups according to the genetic makeup of the cancer cells. Which category a cancer falls into generally determines the best method of treatment. But cancers in one of the four groups—called "basal-like" or "triple-negative" breast cancer (TNBC)—have been particularly tricky to treat. Researchers have developed a potential treatment for TNBC that uses nanodiamonds.
Nitric oxide (NO), a gas with many biological functions in healthy cells, can also help some cancer cells survive chemotherapy. A new study from Massachusetts Institute of Technology (MIT) reveals one way in which this resistance may arise, and raises the possibility of weakening cancer cells by cutting off their supply of NO.
Cancer painfully ends more than 500,000 lives in the United States each year, according to the Centers for Disease Control and Prevention. The scientific crusade against cancer recently achieved a victory under the leadership of University of Missouri Curators’ Professor M. Frederick Hawthorne. Hawthorne’s team has developed a new form of radiation therapy that successfully put cancer into remission in mice. This innovative treatment produced none of the harmful side-effects of conventional chemo and radiation cancer therapies.
A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian or prostate cancer, scientists reported Wednesday. The potential payoff for ordinary people is mostly this: Someday there may be genetic tests that help identify women with the most to gain from mammograms, and men who could benefit most from PSA tests and prostate biopsies.
A huge international effort involving more than 100 institutions and genetic tests on 200,000 people has uncovered dozens of signposts in DNA that can help reveal further a person's risk for breast, ovarian, or prostate cancer, scientists reported Wednesday.
Researchers from Georgia Tech and Children's Healthcare of Atlanta have developed a technique that assists in identifying tumors from normal brain tissue during surgery by staining tumor cells blue. The technique could be critically important for hospitals lacking sophisticated equipment in preserving the maximum amount of normal tissue and brain function during surgery.
Most people who are killed by cancer are victims of the spread of the original cancerous tumor, which is why researchers vigorously search for drugs that can prevent metastases. In a finding that could help accelerate that effort, researchers have found a chemical compound that appears to control cell migration and adhesion, two important characteristics of metastatic cancer cells.
The Food and Drug Administration has approved a new imaging drug to help doctors locate lymph nodes in patients with breast cancer and skin cancer. The drug Lymphoseek from Navidea Biopharmaceuticals Inc. is a radioactive imaging agent that is intended to help determine if breast cancer or melanoma has spread to a patient's lymph nodes.
Early detection is vital for the effective treatment of cancer. In many cases, tell-tale biomarkers are present in the bloodstream long before outward symptoms become apparent. The development of an inexpensive and rapid point-of-care diagnostic test capable of spotting such early biomarkers of disease could save many lives. A research team in Japan working on developing such a test has now produced their most sensitive microRNA detector yet.
Therapeutic and diagnostic in function, so-called “theranostic” particles have been developed by a team in Sweden. These small particles can be loaded with medicine and could be a future weapon for cancer treatment. Because the particles can be seen in magnetic resonance images, they are traceable.
People exposed to the highest doses of radiation during Japan's Fukushima nuclear plant disaster in 2011 may have a slightly higher risk of cancer but one so small it probably won't be detectable, the World Health Organization said in a report released Thursday.
Inspired by a chemical that fungi secrete to defend their territory, Massachusetts Institute of Technology chemists have synthesized and tested several dozen compounds that may hold promise as potential cancer drugs.
Cancer researchers from Rice University suggest that a new man-made drug that’s already proven effective at killing cancer and drug-resistant bacteria could best deliver its knockout blow when used in combination with drugs made from naturally occurring toxins.
A tiny capsule invented at a University of California, Los Angeles laboratory could go a long way toward improving cancer treatment. Devising a method for more precise and less invasive treatment of cancer tumors, the team has developed a degradable nanoscale shell to carry proteins to cancer cells and stunt the growth of tumors without damaging healthy cells.
Low-energy radiation particles, known as beta particles, are often used in radiation treatments for cancer patients. For years, scientists have been studying how to use alpha particles, which are far higher in energy, for the same treatments. The challenge has been finding ways to focus these powerful particles on target cancers without hurting other tissues. A collaboration of scientists have recently created a gold nanoparticle that can transport powerful alpha particles directly to tumors for treatment.
Tiny calcium deposits can be a telltale sign of breast cancer. However, in the majority of cases these microcalcifications signal a benign condition. A new diagnostic procedure developed at Massachusetts Institute of Technology and Case Western Reserve University could help doctors more accurately distinguish between cancerous and noncancerous cases.
The Federal Laboratory Consortium announced this week that the Department of Energy national laboratory in Richland is receiving three 2013 Excellence in Technology Transfer awards in recognition for creating technologies or processes that can store large amounts of renewable energy until it's needed, fight cancer and detect explosives, and then moving the innovations to the marketplace.
The spread of cancer cells may be slowed by targeting the protein km23-1, according to researchers at Penn State University College of Medicine. A motor protein that transports cargo within the cell, km23-1 is also involved in the movement or migration of cells. Migration is necessary for cancer to spread, so understanding this cell movement is important for development of better cancer treatments.
Researchers in Japan and California have built a nanoscale Velcro-like device that captures and releases tumor cells that have broken away from primary tumors and are circulating in the bloodstream. This new nanotechnology could be used for cancer diagnosis and give insight into the mechanisms of how cancer spreads throughout the body.
From an early age, the 2012 Scientist of the Year knew that his knowledge of chemistry could make a difference in medicine. He’s still exploring just how much impact that can be.
Retinoblastoma protein are tumor suppressors that can be dysfunctional in several major types of cancers. Researchers at Michigan State University have discovered that these proteins actually do their best work with one foot in the grave. Most proteins, like living things, become weaker toward the end of their lifecycle. Retinoblastoma proteins instead become stronger.
A glass plate with a nanoscale roughness could be a simple way for scientists to capture and study the circulating tumor cells that carry cancer around the body through the bloodstream. Engineering and medical researchers at the University of Michigan have devised such a set-up, which they say takes advantage of cancer cells' stronger drive to settle and bind compared with normal blood cells.